Sai Life Sciences IPO Details
| IPO Open Date: | December 11, 2024 |
| IPO Close Date: | December 13, 2024 |
| Face Value: | ₹1 Per Equity Share |
| IPO Price Band: | ₹522 to ₹549 Per Share |
| Issue Size: | Approx ₹3,042.62 Crores |
| Fresh Issue: | Approx ₹950.00 Crores |
| Offer for Sale: | Approx 38,116,934 Equity Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Sai Life Sciences IPO Market Lot
The Sai Life Sciences IPO minimum market lot is 27 shares with ₹14,823 application amount. The retail investors can apply up-to 13 lots with 351 shares or ₹192,699 amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 27 | ₹14,823 |
| Retail Maximum | 13 | 351 | ₹192,699 |
| S-HNI Minimum | 14 | 378 | ₹207,522 |
| B-HNI Minimum | 68 | 1,836 | ₹1,007,964 |
Sai Life Sciences IPO Dates
The Sai Life Sciences IPO date is December 11 and the close date is December 13. The Sai Life Sciences IPO allotment will be finalized on December 16 and the IPO listing on December 18.
| IPO Open Date: | December 11, 2024 |
| IPO Close Date: | December 13, 2024 |
| Basis of Allotment: | December 16, 2024 |
| Refunds: | December 17, 2024 |
| Credit to Demat Account: | December 17, 2024 |
| IPO Listing Date: | December 18, 2024 |
Promoters of Sai Life Sciences IPO
The promoters of the company are Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners and Tulip Partners..
About Sai Life Sciences IPO
Established in January 1999, Sai Life Science Limited works with innovative pharma and biotech companies by providing services across drug discovery, development, and manufacturing of small-molecule new chemical entities (NCE). Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRDMO). The company uses its scientific knowledge and skills to deal with critical healthcare challenges. In the future, they aim to develop medicines to treat conditions that are not curable right now and make a huge difference in the future of healthcare. Their services can be customized according to the customer’s needs, whether it’s a small client, a large biotech company, or a global pharmaceutical company making them adaptable and unstoppable. They are growing more in CRDMO than their competitors by earning revenue CAGR (Compound Annual Growth Rate) and EBITDA CAGR from fiscal year 2022 to 2024. They have always delivered a wide set of NCE development programs for their customers over the past 24 years. Quality, price, and responsiveness are the main 3 key areas where they have shown incredible value to its clients.
Sai Life Sciences IPO Company Financial Report
The company reported revenue of ₹1,494.27 crores in 2024 against ₹1,245.11 crore in 2023. The company reported Profit of ₹82.81 crores in 2024 against Profit of ₹9.99 crores in 2023.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹897.74 | ₹888.05 | ₹6.23 | ₹2,164.23 |
| 2023 | ₹1,245.11 | ₹1,228.70 | ₹9.99 | ₹2,186.65 |
| 2024 | ₹1,494.27 | ₹1,385.04 | ₹82.81 | ₹2,275.14 |
| September 2024 | ₹693.35 | ₹656.09 | ₹28.01 | ₹2,476.78 |
Sai Life Sciences IPO Valuation – FY2024
Check Sai Life Sciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 8.49% |
| ROCE: | 10.26% |
| EBITDA Margin: | 20.48% |
| PAT Margin: | 5.65% |
| Debt to equity ratio: | 0.75 |
| Earning Per Share (EPS): | ₹4.57 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 8.50% |
| Net Asset Value (NAV): | ₹53.83 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Divi’s Laboratories Limited | 60.27 | 103.04 | 11.79% | 511.21 | 7,845.00 Cr. |
| Suven Pharmaceuticals Limited | 11.80 | 109.37 | 14.64% | 94.04 | 1,051.35 Cr. |
| Syngene International Limited | 12.71 | 73.59 | 11.98% | 105.91 | 3,488.60 Cr. |
Objects of the Issue
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
- General corporate purposes
Sai Life Sciences IPO Review
- Canara Bank –
- DRChoksey FinServ –
- Emkay Global –
- Hem Securities –
- IDBI Capital –
- Marwadi Shares –
- Nirmal Bang –
- SBICAP Securities –
- Sharekhan –
- SMC Global –
- Sushil Finance –
- Swastika Investmart –
- Ventura Securities –
- Geojit –
- Reliance Securities –
- Capital Market –
- BP Wealth –
- ICICIdirect –
- Choice Broking –
Sai Life Sciences IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: [email protected]
Website: https://kosmic.kfintech.com/ipostatus/
IPO Lead Managers aka Merchant Bankers
- Kotak Mahindra Capital Company Limited
- Jefferies India Private Limited
- Morgan Stanley India Company Pvt Ltd
- Iifl Securities Ltd
Company Address
Sai Life Sciences Limited
Plot No. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal,
Malkajgiri District, Hyderabad-500078
Phone: +9140 6815 6000
Email: [email protected]
Website: https://www.sailife.com/
Sai Life Sciences IPO FAQs
What is Sai Life Sciences IPO?
When Sai Life Sciences IPO will open for subscription?
What is Sai Life Sciences IPO Investors Portion?
How to Apply the Sai Life Sciences IPO?
What is Sai Life Sciences IPO Issue Size?
What is Sai Life Sciences IPO Price Band?
What is Sai Life Sciences IPO Lot Size?
What is the Sai Life Sciences IPO Allotment Date?
What is the Sai Life Sciences IPO Listing Date?
Note: The Sai Life Sciences IPO price band and date are officially announced. The (Sai Life Sciences IPO grey market premium) will be added to the IPO GMP page as it will start).
